20/20 Biolabs, Inc. Revenue 2024–2025
20/20 Biolabs, Inc. annual/quarterly revenue history and growth rate from 2024 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- 20/20 Biolabs, Inc. revenue for the quarter ending March 31, 2026 was 353375, a 36.19% decrease year-over-year.
- 20/20 Biolabs, Inc. annual revenue for 2025 was 2.0 M, a 16.71% increase from 2024.
- 20/20 Biolabs, Inc. annual revenue for 2024 was 1.8 M.
20/20 Biolabs, Inc. (AIDX) — Frequently Asked Questions
20/20 Biolabs, Inc. (AIDX) is a publicly traded US company. It has a market capitalization of $4M. In fiscal 2025 it reported revenue of $2M and net income of -$4M. Explore AIDX's stock price, financial statements, earnings history, margins and key ratios below.
What is 20/20 Biolabs, Inc.'s market cap?
20/20 Biolabs, Inc. (AIDX) has a market capitalization of $4M.
What is the AIDX stock price?
AIDX trades at $0.87 (+10.05% on the day).
How much revenue does 20/20 Biolabs, Inc. make?
20/20 Biolabs, Inc. reported revenue of $2M in fiscal 2025.
Is AIDX profitable?
In fiscal 2025, 20/20 Biolabs, Inc. reported net income of -$4M.